Trial Profile
A 12-week, randomized, subject and investigator blind, placebo-controlled trial to evaluate the effect of CP-866,087 on weight loss in obese, otherwise healthy adult subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs CP 866087 (Primary)
- Indications Obesity
- Focus Biomarker; Therapeutic Use
- Sponsors Pfizer
- 30 Oct 2008 Actual patient number (94) added as reported by ClinicalTrials.gov.
- 19 Feb 2008 Status changed from recruiting to completed.
- 27 Jul 2007 New trial record.